On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer

We addressed a significant unknown feature of circulating tumor DNA (ctDNA), i.e., how ctDNA levels change during chemotherapy, by serially monitoring ctDNA in patients with colorectal cancer during the 48-h application of FOLFOX. Surprisingly, we did not observe a spike in ctDNA as a sign of a responsive tumor, but instead ctDNA levels initially decreased and remained low in patients with stable disease or partial response. Our observations reveal further insights into cell destruction during chemotherapy with important implications for the management of patients.


Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of computer code Data collection Sequencing data in Fastq Format was collected by various Illumina instruments using their proprietary algorithms Data analysis Reads are trimmed using fastx_trimmed (v 0.0.13) Alignments are carried out using bwa mem (v. 0.7.15-r1140) BedTools is used for calculating genome coverages (v.2.24.0) samtools is used for downsampling sequence reads (v.1.3.1) CNV analysis has beend one using plasma seq (github.com/PeterUlz/PlasmaSeq ) ichorCNA is implemented as an R package and can be obtained at https://github.com/broadinstitute/ichorCNA. R (version 4.0.2) and the ggpubr package (version 0.4.0) For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability The following sequencing raw data sets have been deposited at the European Genome-phenome Archive (EGA; http://www.ebi.ac.uk/ega/) under the accession nature research | reporting summary April 2020 number EGAS00001004213: 1: sWGS of CRC patients (EGAD000010061012), 2: Mutation analysis data (AVENIO ctDNA Targeted Kit: EGAD00001006103, SiMSenseq approach: EGAD00001006104, Deep sequencing: EGAD00001006105).

Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design
All studies must disclose on these points even when the disclosure is negative.

Sample size
No sample size estimation has been performed, since this is an early pilot-study which is to demonstrate feasibility rather than discriminatory power of this analysis. This also means that we are unable to specify or estimate effect sizes

Eukaryotic cell lines Policy information about cell lines Cell line source(s)
State the source of each cell line used.

Authentication
Describe the authentication procedures for each cell line used OR declare that none of the cell lines used were authenticated.

Mycoplasma contamination
Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.

Commonly misidentified lines (See ICLAC register)
Name any commonly misidentified cell lines used in the study and provide a rationale for their use.

nature research | reporting summary
April 2020 Palaeontology and Archaeology

Specimen provenance
Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).

Specimen deposition
Indicate where the specimens have been deposited to permit free access by other researchers.

Dating methods
If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.
Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Ethics oversight
Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.
Note that full information on the approval of the study protocol must also be provided in the manuscript.

Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Laboratory animals
For laboratory animals, report species, strain, sex and age OR state that the study did not involve laboratory animals.

Wild animals
Provide details on animals observed in or captured in the field; report species, sex and age where possible.

Ethics oversight
Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.
Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants
Policy information about studies involving human research participants

Population characteristics
We studied a cohort of 13 patients (DR1-DR13) with the inclusion criteria of metastasized CRC and progressive disease under one of the most widely used chemotherapies, i.e. FOLFOX. All relevant clinical data are summarized in the Supplementary Note that full information on the approval of the study protocol must also be provided in the manuscript.

Dual use research of concern
Policy information about dual use research of concern Hazards Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to: